Related references
Note: Only part of the references are listed.Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis
Katrina Abuabara et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A. B. Kimball et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials
T. Tzellos et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
Jashin J. Wu et al.
ARCHIVES OF DERMATOLOGY (2012)
The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives
A. D. Burden et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study
Ole Ahlehoff et al.
EUROPEAN HEART JOURNAL (2012)
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis
Alexa B. Kimball et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis
David M. Pariser et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Melanoma in situ in a private practice setting 2005 through 2009: Location, lesion size, lack of concern
Sherea M. Stricklin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review
E. Archier et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease
Renata Micha et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis A Comprehensive Analysis of All Adalimumab Exposure in All Clinical Trials
Craig Leonardi et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2011)
Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events
Nehal N. Mehta et al.
AMERICAN JOURNAL OF MEDICINE (2011)
The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study
K. Abuabara et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events A Meta-analysis of Randomized Controlled Trials
Caitriona Ryan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients
Eric A. Engels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Psoriasis and Vascular Disease-Risk Factors and Outcomes: A Systematic Review of the Literature
Rita V. Patel et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2011)
Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort
Marlies Wakkee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Skin cancer in solid organ transplant recipients: Advances in therapy and management Part I. Epidemiology of skin cancer in solid organ transplant recipients
Fiona O'Reilly Zwald et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Cutaneous Melanoma In Situ: Translational Evidence from a Large Population-Based Study
Simone Mocellin et al.
ONCOLOGIST (2011)
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Sarah L. Westlake et al.
RHEUMATOLOGY (2011)
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Anne Puel et al.
SCIENCE (2011)
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
Nehal N. Mehta et al.
EUROPEAN HEART JOURNAL (2010)
IL-23 and IL-17A, but Not IL-12 and IL-22, Are Required for Optimal Skin Host Defense against Candida albicans
Shinji Kagami et al.
JOURNAL OF IMMUNOLOGY (2010)
Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis
Michael S. Krathen et al.
JOURNAL OF RHEUMATOLOGY (2010)
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Sarah L. Westlake et al.
RHEUMATOLOGY (2010)
Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis
Robert Bissonnette et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2009)
Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Case-Control Analysis
Yolanda B. Brauchli et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Treatments for psoriasis and the risk of malignancy
Rita V. Patel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inborn errors of IL-12/23- and IFN-γ-mediated immunity:: molecular, cellular, and clinical features
Orchidee Filipe-Santos et al.
SEMINARS IN IMMUNOLOGY (2006)
Risk of myocardial infarction in patients with psoriasis
Joel M. Gelfand et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
IL-23 promotes tumour incidence and growth
John L. Langowski et al.
NATURE (2006)
Human host genetic factors in mycobacterial and Salmonella infection:: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity
E van de Vosse et al.
MICROBES AND INFECTION (2006)
Current concepts - Basal-cell carcinoma.
AI Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies
D Geng et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2005)
Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks
L Naldi et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
AB Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The role of interleukin-12 in human infectious diseases: only a faint signature
C Fieschi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses
G Trinchieri et al.
IMMUNITY (2003)
Share Paper
